HLS vs. ACB, WEED, FIRE, OGI, CPH, EPI, ICC, RIV, LEAF, and CRDL
Should you be buying HLS Therapeutics stock or one of its competitors? The main competitors of HLS Therapeutics include Aurora Cannabis (ACB), Canopy Growth (WEED), Supreme Cannabis (FIRE), Organigram (OGI), Cipher Pharmaceuticals (CPH), ESSA Pharma (EPI), ICC Labs (ICC), RIV Capital (RIV), Leaf Mobile (LEAF), and Cardiol Therapeutics (CRDL). These companies are all part of the "drug manufacturers - specialty & generic" industry.
HLS Therapeutics vs. Its Competitors
Aurora Cannabis (TSE:ACB) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.
Aurora Cannabis currently has a consensus price target of C$8.75, indicating a potential upside of 39.55%. HLS Therapeutics has a consensus price target of C$4.50, indicating a potential downside of 8.35%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, equities analysts plainly believe Aurora Cannabis is more favorable than HLS Therapeutics.
In the previous week, Aurora Cannabis had 1 more articles in the media than HLS Therapeutics. MarketBeat recorded 1 mentions for Aurora Cannabis and 0 mentions for HLS Therapeutics. HLS Therapeutics' average media sentiment score of 0.67 beat Aurora Cannabis' score of 0.00 indicating that HLS Therapeutics is being referred to more favorably in the news media.
13.4% of Aurora Cannabis shares are held by institutional investors. Comparatively, 65.2% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Aurora Cannabis has a beta of 2.71, suggesting that its stock price is 171% more volatile than the S&P 500. Comparatively, HLS Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.
HLS Therapeutics has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than HLS Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aurora Cannabis has a net margin of -22.55% compared to HLS Therapeutics' net margin of -38.70%. Aurora Cannabis' return on equity of -8.36% beat HLS Therapeutics' return on equity.
Summary
Aurora Cannabis beats HLS Therapeutics on 10 of the 16 factors compared between the two stocks.
Get HLS Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HLS Therapeutics Competitors List
Related Companies and Tools
This page (TSE:HLS) was last updated on 7/17/2025 by MarketBeat.com Staff
